My Cart

Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
TIT-H82F1-25ug
$360.00
TIT-H82F1-200ug
$1565.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Synonyms

    TIGIT, VSIG9, VSTM3

  • Source

    Biotinylated Human TIGIT, Fc,Avitag (TIT-H82F1) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).

    Predicted N-terminus: Met 22

    Request for sequence
  • Molecular Characterization

    TIGIT Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 41.3 kDa. The protein migrates as 45-55 kDa under reducing (R) condition, and 85-115 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    TIGIT SDS-PAGE

    Biotinylated Human TIGIT, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    TIGIT SEC-MALS

    The purity of Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) is more than 85% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     TIGIT ELISA

    Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) with a linear range of 10-156 ng/mL (QC tested).

    Protocol
  •  TIGIT ELISA

    Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD5-H5254): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.08116 μg/mL (Routinely tested).

    Protocol
  •  TIGIT ELISA

    Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Fc Tag (Cat. No. CD5-H5251): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.06065 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-FACS

     TIGIT FACS

    FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Recent Advances

 
Drug Development Progress
  • English Name:

    T cell immunoglobulin and ITIM domains

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    41 Details

  • Highest Development Stage:

    Phase 3 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland